CEACAM-6

CEACAM-6 Overview

English NameCarcinoembryonic antigen related cell adhesion molecule 6Approved Drugs0
Drugs in Clinical Trials3Target SynonymCEACAM6,CD66c,NCA,Carcinoembryonic Antigen Related Cell Adhesion Molecule 6,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 (Non-Specific Cross Reacting Antigen),Normal Cross-Reacting Antigen,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6,Non-Specific Crossreacting Antigen,Cluster Of Differentiation 66c,CD66c Antigen,CEAL,CEA Cell Adhesion Molecule 6
Highest Development StagePhase 2 Clinical
English NameCarcinoembryonic antigen related cell adhesion molecule 6
Target SynonymCEACAM6,CD66c,NCA,Carcinoembryonic Antigen Related Cell Adhesion Molecule 6,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 (Non-Specific Cross Reacting Antigen),Normal Cross-Reacting Antigen,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6,Non-Specific Crossreacting Antigen,Cluster Of Differentiation 66c,CD66c Antigen,CEAL,CEA Cell Adhesion Molecule 6
Approved Drugs0
Drugs in Clinical Trials3
Highest Development StagePhase 2 Clinical

CEACAM-6 Product List

  • Product Category

    Protein (5)

  • Product Status

    Launched (5)

  • Species

    Human (4)Rhesus macaque (1)

  • Tag

    His Tag (2)His Tag & Avi Tag (1)Fc Tag (1)Fc Tag & Avi Tag (1)

  • Conjugate

    Unconjugated (3)Biotin-labeled (2)

CEACAM-6 Background

Carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) (CEACAM6) is also known as CD66c (Cluster of Differentiation 66c), CEAL, NCA, and is one of seven human CEACAM family members within the immunoglobulin superfamily. In humans, CEACAMs include type I transmembrane proteins (CEACAM1, CEACAM3, and CEACAM4) and GPI-linked molecules (CEACAM5 through CEACAM8). There is no human CEACAM2. CEACAM 6 contains one N-terminal V-type Ig-like domain (N domain), followed by two C2-type Ig-like domains. It shows considerable glycosylation, including (sialyl) LewisX, which mediates binding to E-selectin, galectins and some bacterial fimbrae. CEACAM-6 is expressed by granulocytes and their progenitors. It is also expressed by epithelia of various organs and is upregulated in pancreatic and colon adenocarcinomas, as well as hyperplastic polyps. Resistance to adhesion-related apoptosis in tumor cells is conferred in the condition of CEACAM6 overexpression.

CEACAM-6 Synonyms

CEACAM6,CD66c,CEAL,NCA

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
NEO-201NEO-201Phase 2 ClinicalNational Cancer Institute, Precision Biologics IncCarcinoma, Non-Small-Cell Lung; Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms; Uterine Neoplasms
Details
EBC-129EBC129; EBC-129Phase 1 ClinicalExperimental Drug Development CentreSolid tumours
Details
DNP-002DNP-002Phase 1 ClinicalDinonaSolid tumours
Details
  • Overview
  • Product List
  • Clinical Drug Information
Contact Us

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호